In-vitro Colorectal Cancer Screening Tests Market To Reach $1.12 Billion By 2030

In-vitro Colorectal Cancer Screening Tests Market Growth & Trends

The global in-vitro colorectal cancer screening tests market size is expected to reach USD 1.12 billion by 2030, expandingat a CAGR of 3.02% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising number of novel screening models to combat the increasing incidences of colon and rectal malignancy cases is the major factor influencing the market growth. The emergence of newly developed genetic and biomarker tests such as tumor M2-PK stool tests and methylated gene testing is anticipated to drive the adoption rate of tumor diagnostic models.

The increasing incidence of colorectal malignancy is a significant driver for the growth of the segment. For example, according to data released by the National Cancer Center Japan in June 2022, it was projected that there would be approximately 1,019,000 new cases of cancer in Japan in 2022, with Colorectal Cancer (CRC) accounting for an estimated 158,200 new cases. Similarly, data updated by Cancer Australia in August 2022 indicated that 15,713 new cases of CRC were expected to be diagnosed in Australia in 2022, with 8,300 cases among males and 7,413 cases among females. As a result, the increasing prevalence of colorectal malignance is anticipated to drive the demand for colonoscopy devices.

The implementation of various initiatives by public organizations to promote screening has positively impacted the demand for in-vitro CRC screenings. For instance, according to reports from Cancer.org, healthcare systems in California continued to provide FIT kits (fecal immunochemical tests) during the months of April and May 2020, and the response rates for FIT remained high despite the onset of the COVID-19 pandemic. Additionally, the European Cancer community has mobilized its resources to evaluate, address, and mitigate the adverse effects of COVID-19 on screening. These efforts have contributed to the sustained demand for in-vitro screening tests.

Furthermore, market growth is expected to be driven by the increasing number of product launches by major market players. These product launches are aimed at providing access to technologically advanced and innovative products. For instance, Pillar Biosciences, Inc. received FDA approval for the ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) in July 2021 for the detection of CRC.

 Request a free sample copy or view report summary: In-vitro Colorectal Cancer Screening Tests Market Report

In-vitro Colorectal Cancer Screening Tests Market Report Highlights

• Based on test type, fecal occult blood testing segment held the largest share of the market in 2022 due to their wider usage and easy applicability by large customer base

• Among FOB test segment, immuno-FOB ELISA test held a significant share in 2022, as immunological testing offers more accuracy than conventional guaiac FOB stool test

• Biomarker tests are expected to gain revenue share over the forecast period due to the emergence of noninvasive screening procedures

• Tumor M2-PK stool test generated maximum revenue in 2022 due to recent product introduction such as ScheBo Tumor M2-PK Stool Test by ScheBo Biotech AG

• In CRC DNA screening test vertical, panel DNA tests are gaining ground as these are advanced genetic screening tests, thus contributing the maximum revenue share

• North America held the largest share of the market in 2022, which can be attributed to high adoption rate of these products in clinical workflow for detection of melanoma

• Key players operating in the market include Abbott Laboratories; Quest Diagnostics; Siemens AG; Randox Laboratories; Kyowa Medex; and GeneNews and are constantly focusing on product launches and geographical expansion to gain higher share in the market

• In December 2022, Guardant Health, Inc., a company based in the United States, reported positive findings from the ECLIPSE study. This extensive study involved more than 20,000 patients and aimed to assess the effectiveness of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults 

In-vitro Colorectal Cancer Screening Tests Market Segmentation

Grand View Research has segmented the global in-vitro colorectal cancer screening tests market based on test type and region:

In-vitro Colorectal Cancer Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Fecal Occult Blood Tests   

  • Guaiac FOB Stool Test

  • Immuno-FOB Agglutination Test

  • Lateral Flow Immuno-FOB Test

  • Immuno-FOB ELISA Test

• Biomarker tests      

  • Tumor M2-PK Stool Test

  • Transferrin Assays

• CRC DNA Screening Tests

  • Methylated Gene Testing

  • Panel DNA Tests

In-vitro Colorectal Cancer Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • France

  • Italy

  • Russia

  • Spain

  • UK

  • Netherlands

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the In-vitro Colorectal Cancer Screening Tests Market

• Abbott

• Epigenomics

• Beckman Coulter, Inc.

• Eiken Chemical Co., Ltd.

• Sysmex Corporation

• Siemens Healthcare GmbH

• Quest Diagnostics Incorporated

• Oncocyte Corporation

• Merck KGaA

• Immunostics Inc.

• Kyowa Kirin Co., Ltd.

• Randox Laboratories Ltd.

• R-Biopharm AG